Skip to main content

Mycoplasma genitalium in Malaysia: Symptoms, Testing & Treatment

Mycoplasma genitalium (Mgen) is an emerging bacterial STI (also called STD) causing urethritis in men and cervicitis/PID in women. Up to 70% of infections are asymptomatic. Macrolide resistance now exceeds 50% globally, so resistance-guided antibiotic therapy is essential. Diagnosis is by NAAT with macrolide-resistance testing.

Book a confidential appointment

Medically reviewed by · MD, MMC-registered · Pathogen: Mycoplasma genitalium · ICD-10 A63.8

Thoughtful editorial portrait of a man in his 30s - Mycoplasma genitalium testing and care.

What is mycoplasma genitalium?

Mycoplasma genitalium is a sexually transmitted bacterium identified in the 1980s and increasingly recognised as a major cause of urethritis in men and cervicitis, pelvic inflammatory disease and infertility in women.

Mgen lacks a cell wall (so beta-lactam antibiotics don't work) and has developed widespread macrolide and increasing fluoroquinolone resistance. Resistance-guided therapy and test-of-cure are now standard.

Pathogen: Mycoplasma genitalium (Cell-wall-deficient bacterium, Mollicutes).

How it spreads

  • Unprotected vaginal, anal or oral sex
  • Sharing sex toys
  • Not transmitted by casual contact

Who is at risk? Should I get tested?

  • Sexually active people aged 15-40
  • Multiple or new sexual partners
  • Persistent/recurrent urethritis or cervicitis after standard treatment
  • Pelvic inflammatory disease
  • Partner with diagnosed Mgen
  • Men who have sex with men (rectal carriage)

Should I get tested? Quick self-check

Answer the questions below - your concierge can advise on the next step.

  • Have you had urethral or vaginal discharge?
  • Have you had persistent or recurrent urethritis despite previous treatment?
  • Do you have pelvic pain, bleeding between periods, or pain during sex (women)?
  • Have you had new sexual partners in the past 6 months?
  • Has a partner been diagnosed with Mycoplasma genitalium?

Symptoms

  • Up to 70% of infections are asymptomatic
  • Urethral discharge (men)
  • Painful urination
  • Cervicitis: bleeding between periods or after sex (women)
  • Pelvic pain, lower abdominal discomfort (women)
  • Rectal pain or discharge (rectal infection)
  • Often mistaken for chlamydia or recurrent UTI

Asymptomatic in men

Up to 70% of Mgen infections in men are asymptomatic

Asymptomatic in women

Around 70-90% of Mgen infections in women are asymptomatic, but Mgen is increasingly linked to pelvic inflammatory disease and tubal-factor infertility

Source: see reference [1] below.

Malaysia statistics

Mgen is not yet a notifiable STI in Malaysia; epidemiology data is from research cohorts.
Mgen prevalence in symptomatic NSU cases~10-30%[1]
Global macrolide (azithromycin) resistance rate>50% and rising[2]
Fluoroquinolone (moxifloxacin) resistanceEmerging, ~10-15% in some regions[2]
Pelvic inflammatory disease cases linked to Mgen~10% of PID worldwide[1]

Testing & window period

Method

Nucleic acid amplification test (NAAT / PCR) with macrolide-resistance testing where available. Routine screening is NOT recommended - test on indication (symptoms, persistent NSU, PID, sexual contact of known case).

Specimen

First-void urine, vulvovaginal/cervical swab, rectal swab

Window period

Testable from 1-2 weeks after exposure.

Retest

Test of cure 4 weeks after treatment is mandatory - high rates of resistance and treatment failure.

Treatment

First-line: Resistance-guided two-stage oral antibiotic therapy, prescribed by our medical team. The specific antibiotics are selected once the macrolide-resistance result is available.

Alternative: Second-line regimens are available for macrolide- and fluoroquinolone-resistant cases, in some situations under specialist guidance.

Partner management: Sexual partners from the past 60 days should be tested for Mgen and treated based on their own result. Empirical partner treatment is no longer recommended because of resistance.

Abstain from sex for 7 days after treatment is complete and until test of cure is negative. Avoid empirical single-antibiotic therapy without resistance testing - this drives resistance.

Follow-up

  • Test of cure at 4 weeks (NAAT) - mandatory
  • If still positive, escalate to next-line therapy with resistance retesting
  • Screen for other STIs
  • Female patients: rule out PID if pelvic symptoms

Prevention

  • Consistent condom use
  • Avoid sharing sex toys
  • Test on indication only - routine asymptomatic Mgen screening drives resistance
  • Resistance-guided treatment
  • Partner testing rather than empirical treatment

Vaccination

No vaccine exists for Mycoplasma genitalium.

See also: Non-specific urethritis (NSU), STI testing options

FAQ

Mycoplasma genitalium - frequently asked questions

Clear answers, written by our clinical team. Tap any question for its direct permalink, or reach out to your Personal Concierge for anything else.

  1. Should I be tested for Mycoplasma genitalium routinely?

    No. Major guidelines (CDC, BASHH) recommend testing on indication only: symptomatic urethritis or cervicitis, persistent symptoms after first-line antibiotics, pelvic inflammatory disease, or known partner with Mgen. Routine asymptomatic screening drives resistance.

  2. Why is Mycoplasma genitalium so difficult to treat?

    Mgen has no cell wall (so penicillin-family antibiotics don't work) and has rapidly developed resistance to azithromycin (>50% globally) and increasingly to moxifloxacin. Resistance-guided treatment and test of cure are essential.

  3. Will my Mgen come back?

    Treatment failure or reinfection is common - up to 20-30% even with first-line therapy. This is why test of cure at 4 weeks is mandatory, and resistance testing guides second-line therapy.

  4. Can Mgen cause infertility?

    Yes - in women, untreated Mgen is increasingly linked to pelvic inflammatory disease and tubal-factor infertility. In men, the long-term reproductive impact is less clear but epididymitis is documented.

  5. Do I need to treat my partner?

    Partners should be tested rather than empirically treated, because Mgen testing now includes resistance profiling that guides treatment. Empirical single-antibiotic therapy worsens the global resistance problem.

  6. How is Mgen care arranged at Hisential?

    Your personal health concierge coordinates NAAT testing (ideally with resistance profiling), resistance-guided treatment, partner support and mandatory test of cure in one confidential pathway.

Still have a question?

Your Personal Concierge replies within one business day - confidentially.

Message your personal conciergeFind a clinic

References

  1. [1] BASHH UK. Mycoplasma genitalium national guideline (2018, updated).
  2. [2] Jensen JS et al. European guideline on Mycoplasma genitalium infections. J Eur Acad Dermatol Venereol.
  3. [3] Centers for Disease Control and Prevention. Sexually Transmitted Infections Treatment Guidelines, 2021.

Other STI conditions

Browse our other in-depth STI guides - each covers symptoms, asymptomatic statistics by sex, Malaysia data, testing windows, treatment and prevention.

See all STI conditions →

Your personal health concierge

One dedicated contact coordinates your testing, treatment, partner support and follow-up - discreetly and end-to-end. All care is delivered by our MMC-registered medical team.

Book a confidential appointment